Regenerative Medicine

Instead of just covering up joint pain with medicine, regenerative medicine uses biologics derived from Wharton’s Jelly/human umbilical cord that is rich is cytokines, growth factors and proteins to actually regenerate human tissue

Do you suffer from pain in your joints and tendons?

At Advanced Health NY, we are pleased to offer a modern, science based regenerative medicine program for treating pain and inflammation. Medical literature and studies show how effective these treatments are and they are approved by the FDA and covered by most insurances.

Treatment with regeneratives has been effective in alleviating painful symptoms of arthritis and other forms of pain. Patients generally feel relief throughout the treatment period, are able to function better and even feel better emotionally. Unlike steroids which only provide immediate relief of pain, regeneratives work by regenerating human tissue, providing repair and relief over time, that lasts many years.

WHARTON’S JELLY ALLOGRAFTS

Regenerative medicine products are “game changers” with their healing capabilities. Now with Regenative Labs PROTEXT™ Flowables, you can harness the powerful properties of Wharton’s Jelly (WJ) derived from human umbilical cord tissue.

Wharton’s Jelly has unique characteristics that enhance structural support in body areas such as ligaments and joints, as well as providing insulation and lubrication to these structures and surrounding areas.

Wharton’s Jelly products contain mesenchymal stem cells, growth factors, and other essential molecules necessary
for regeneration. They consist of high levels of extracellular matrix components; mainly collagen, hyaluronic acid and proteoglycans. Additionally, their vast reservoir of many peptide growth factors are essential for healing and regrowth.

Regenative Labs products from Umbilical Cord tissue present a viable and more effective alternative to NSAID and steroid injections in reducing or eliminating the often debilitating pain associated with musculoskeletal injuries.

How Does It Work?

The biological components of regeneratives contain the building blocks (proteins, growth factors, antibodies) for stem cell activation and dedifferentiation. These mesenchymal and stromal cells used by your body to build, repair and regenerate human tissue.

Where do these regeneratives come from?

Advanced Health NY has chosen PROTEXT™ as its main regenerative treatment. PROTEXT™ is an human umbilical cord derived liquid allograft. It is sterile, safe, and obtained from consenting mothers at scheduled c-sections. PROTEXT™ does not utilize any fetal tissue.

Is it safe?

PROTEXT™ is obtained and processed using a carefully controlled and stringent process. There are no side effects associated with this type of treatment.

Is it comfortable?

PROTEXT™ is designed to be comfortably injected into a joint or soft tissue with minimal discomfort.

What conditions can benefit from PROTEXT™?

  • Osteoarthritis

  • Back Pain

  • Ligament Injury

  • Hip Pain

  • Knee Pain

  • Elbow Pain

  • Shoulder Pain

  • Tennis Elbow

  • Plantar Fasciitis

  • Carpal Tunnel

  • Rotator Cuff Pain

  • Tendinitis 

 

ADVANTAGES OF PROTEXT™

  • PROTEXT™ is Regenative LabsTM’ most concentrated Wharton’s Jelly/human umbilical cord product.

  • Using PROTEXT™ is less invasive compared to Platelet Rich Plasma (PRP), bone marrow aspiration or adipose tissue extraction. No harvesting of tissue is required.

  • Umbilical Cord related products have higher concentrations of growth factors, peptides and hyaluronic acid compared to PRP and amniotic based products.

  • Wharton’s Jelly has a high anti-inflammatory property due to its large concentrations of growth factors and cytokines.

  • Wharton’s Jelly contains high levels of hyaluronic acid which assists in lubricating, supporting and aiding mobility in joints and tendons.

  • Studies report that mesenchymal stem cell products isolated from Umbilical Cord tissue are more effective that those isolated from adults.

 

PROTEXT™ treatment may be covered by Medicare, as well as other insurance plans. Generally six to eight weeks of physical therapy is required for medical necessity. Some insurances require a cortisone injection to be tried first. At this time Medicare is reviewing coverage of this product and will not reimburse for it, however, cash pricing is available.

CLINICAL LITERATURE HAS SHOWN THAT THE USE OF WHARTON’S JELLY CAN BE EXTREMELY EFFECTIVE

  • Derived from the powerful Wharton’s Jelly of the Human Umbilical Cord

  • Known for its growth factors, high molecular weight hyaluronic acid, structural proteins, cytokines, and mesenchymal stem cells

  • Provides structural support for tissues and joints

  • Exciting alternative regenerative medicine therapy

  • Used widely within orthopedic, sports medicine, and

    pain management practices​

Relevant Studies:

Collagen and Glycosaminoglycans of Wharton’s Jelly

Neonatology. 1997;71(1):11-21

​SonolewskiK,BankowskiE,ChyczewskiL,JaworkskiS

Whartons Jelly as a reservoir of peptide growth factors

Placenta. 2005;26(10):747-752.

Sonolewski K, Bankowski E, Chyczewski L, Jaworkski S

 

 

Adult MSC for Tissue Engineering vs Regenerative Medicine

Jnl of Cellular Physiology

Caplan, AI, 2007

Amniotic fluid and placental membranes: unexpected sources of highly multipotent cells

Gestational tissue such as the placenta, placental membranes, and amniotic fluid are usually discarded following birth. Recently, researchers have identified gestational tissue as an untapped source of stem cells that are highly multipotent and possess potent immunosuppressive properties. Placental mesenchymal stem cells (MSCs), human amnion epithelial cells (hAECs), and amniotic fluid-derived stem cells (AFSCs) have been shown to differentiate into various cell types including adipogenic, osteogenic, myogenic, endothelial, pulmonary, neurogenic, hepatogenic, cardiac, and pancreatic lineages. Their immunomodulatory properties suggest that gestational stem cells may have an important application in the treatment of various inflammatory diseases such as graft versus host and autoimmune diseases. In clinical and preclinical studies, gestational stem cells have shown efficacy in the treatment of Crohn disease, lung disease, diabetes, repair of bone defects, heart disease, kidney disease, neural degeneration, and blood disorders. Stem cells derived from the placenta, placental membranes, and amniotic fluid are a valuable resource for the field of regenerative medicine.     

https://pubmed.ncbi.nlm.nih.gov/23329638/

Stem cells from amniotic fluid--Potential for regenerative medicine

Regenerative medicine has recently been established as an emerging field focussing on repair, replacement or regeneration of cells, tissues and whole organs. The significant recent advances in the field have intensified the search for novel sources of stem cells with potential for therapy. Recently, researchers have identified the amniotic fluid as an untapped source of stem cells that are multipotent, possess immunomodulatory properties and do not have the ethical and legal limitations of embryonic stem cells. Stem cells from the amniotic fluid have been shown to differentiate into cell lineages representing all three embryonic germ layers without generating tumours, which make them an ideal candidate for tissue engineering applications. In addition, their ability to engraft in injured organs and modulate immune and repair responses of host tissues suggest that transplantation of such cells may be useful for the treatment of various degenerative and inflammatory diseases affecting major tissues/organs. This review summarises the evidence on amniotic fluid cells over the past 15 years and explores the potential therapeutic applications of amniotic fluid stem cells and amniotic fluid mesenchymal stem cells.

https://pubmed.ncbi.nlm.nih.gov/26542929/

Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Past, Present, and Future

The concept of Regenerative Medicine combined with Cell based Therapy and Tissue Engineering represents the fourth pillar of healthcare and provides a promising approach for the treatment of serious diseases. Recently, cell based therapies are focused on the use of mesenchymal stem/stromal cells (MSCs). Human MSCs, that represent a mesoderm derived population of progenitors, are easily expanded in culture. They are capable to differentiate into osteoblasts, chondrocytes, and adipocytes and exhibit the potential to repair or regenerate damaged tissues. The best characterized source of human MSCs to date is the bone marrow; recently, fetal sources, such as amniotic fluid, umbilical cord, amniotic membranes, or placenta, have also attracted increased attention. Thus, MSCs may represent a valuable tool for tissue repair and cell therapeutic applications. To this end, the main focus of this review is to summarize and evaluate the key characteristics, the sources, and the potential use of MSCs in therapeutic approaches and modalities.

https://pubmed.ncbi.nlm.nih.gov/28520465/

iu.png